CDNA Valuation

CareDx Inc

Add to Watchlist

Advanced Chart

13.660

+0.55(4.195%)1D

Overview
Forecast
Valuation
Earnings

CDNA Relative Valuation

CDNA's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, CDNA is overvalued; if below, it's undervalued.

Historical Valuation

CareDx Inc (CDNA) is now in the Fair zone, suggesting that its current forward PS ratio of 1.77 is considered Fairly compared with the five-year average of 37.78. The fair price of CareDx Inc (CDNA) is between 11.52 to 63.92 according to relative valuation methord.

Relative Value

Fair Zone

11.52-63.92

Current Price：13.32

Fair

17.63

Trailing

Forward

12.39

EV/EBITDA

CareDx Inc. (CDNA) has a current EV/EBITDA of 12.39. The 5-year average EV/EBITDA is 45.37. The thresholds are as follows: Strongly Undervalued below -203.30, Undervalued between -203.30 and -78.96, Fairly Valued between 169.71 and -78.96, Overvalued between 169.71 and 294.05, and Strongly Overvalued above 294.05. The current Forward EV/EBITDA of 12.39 falls within the Historic Trend Line -Fairly Valued range.

-23.81

EV/EBIT

CareDx Inc. (CDNA) has a current EV/EBIT of -23.81. The 5-year average EV/EBIT is -45.47. The thresholds are as follows: Strongly Undervalued below -161.46, Undervalued between -161.46 and -103.47, Fairly Valued between 12.53 and -103.47, Overvalued between 12.53 and 70.52, and Strongly Overvalued above 70.52. The current Forward EV/EBIT of -23.81 falls within the Historic Trend Line -Fairly Valued range.

1.74

CareDx Inc. (CDNA) has a current PS of 1.74. The 5-year average PS is 5.34. The thresholds are as follows: Strongly Undervalued below -3.36, Undervalued between -3.36 and 0.99, Fairly Valued between 9.68 and 0.99, Overvalued between 9.68 and 14.03, and Strongly Overvalued above 14.03. The current Forward PS of 1.74 falls within the Historic Trend Line -Fairly Valued range.

17.02

P/OCF

CareDx Inc. (CDNA) has a current P/OCF of 17.02. The 5-year average P/OCF is -4.98. The thresholds are as follows: Strongly Undervalued below -359.63, Undervalued between -359.63 and -182.31, Fairly Valued between 172.35 and -182.31, Overvalued between 172.35 and 349.67, and Strongly Overvalued above 349.67. The current Forward P/OCF of 17.02 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

CareDx Inc. (CDNA) has a current P/FCF of 0.00. The 5-year average P/FCF is -0.86. The thresholds are as follows: Strongly Undervalued below -69.98, Undervalued between -69.98 and -35.42, Fairly Valued between 33.70 and -35.42, Overvalued between 33.70 and 68.26, and Strongly Overvalued above 68.26. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

CareDx Inc (CDNA) has a current Price-to-Book (P/B) ratio of 2.13. Compared to its 3-year average P/B ratio of 2.46 , the current P/B ratio is approximately -13.36% higher. Relative to its 5-year average P/B ratio of 4.43, the current P/B ratio is about -51.84% higher. CareDx Inc (CDNA) has a Forward Free Cash Flow (FCF) yield of approximately 1.68%. Compared to its 3-year average FCF yield of -2.90%, the current FCF yield is approximately -157.84% lower. Relative to its 5-year average FCF yield of -2.03% , the current FCF yield is about -182.82% lower.

2.22

P/B

Median3y

2.46

Median5y

4.43

1.70

FCF Yield

Median3y

-2.90

Median5y

-2.03

Competitors Valuation Multiple

The average P/S ratio for CDNA's competitors is 3.19, providing a benchmark for relative valuation. CareDx Inc Corp (CDNA) exhibits a P/S ratio of 1.74, which is -45.24% above the industry average. Given its robust revenue growth of -6.06%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Organogenesis Holdings Inc

1.14

-22.44%

653.32M

Performance Decomposition

Market capitalization of CDNA decreased by 57.34% over the past 1 year. The primary factor behind the change was an decrease in Margin Expansion from -5.01 to -9.88.

The secondary factor is the Revenue Growth, contributed -6.06%to the performance.

Overall, the performance of CDNA in the past 1 year is driven by Margin Expansion. Which is more sustainable.

-6.06%

92.27M → 86.68M

Revenue Growth

97.21%

-5.01 → -9.88

Margin Expansion

-148.49%

-28.24 → 13.69

P/E Change

-57.34%